New drug combo aims to outsmart resistant lung cancer
NCT ID NCT07315113
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-phase trial tests a new oral drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutated non-small cell lung cancer that has progressed on prior osimertinib. The main goals are to check safety and see if the combination can shrink tumors or control the disease. Because it is a Phase 1 study, the focus is on finding the right dose and watching for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NXP900 combined with osimertinib
- What this could lead to
- If it works, this could point toward a new combination treatment for advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone.
- What could go wrong
- This is a very early Phase 1b trial with only 18 participants, so it is primarily testing safety and dosing. The combination may not shrink tumors or may cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maryland Oncology Hematology
RECRUITINGCalverton, Maryland, 20705, United States
-
Massachusetts General Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Willamette Valley Cancer Institute and Research Center
RECRUITINGEugene, Oregon, 97401, United States